Product Name,Synonyms,CAS Number,M. Wt,Target,Pathway,Biological Activity,Formula,Solubility,Concentration,Research Area,Clinical Information,SMILES
H3B-6527,,1702259-66-2,629.54,FGFR,Protein Tyrosine Kinase/RTK,"H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity[1].",C29H34Cl2N8O4,DMSO : 2.5 mg/mL (3.97 mM; Need ultrasonic),2mM,Cancer,Phase 1,C=CC(NC1=CC(N2CCN(CC)CC2)=CC=C1NC3=NC=NC(N(C(NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=O)C)=C3)=O
BPI-9016M,,1528546-94-2,460.43,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma[1][2].",C25H18F2N4O3,DMSO : 100 mg/mL (217.19 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1=CNC=C(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=C5C(NCC5)=NC=C4)C(F)=C3
Zongertinib,BI 1810631,2728667-27-2,535.6,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].",C29H29N9O2,DMSO : 30.77 mg/mL (57.45 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCL and heat to 60°C),10mM,Cancer,Launched,O=C(NC1CCN(CC1)C2=NC=C3N=CN=C(C3=N2)NC4=CC=C(C(C)=C4)OC5=CC(N=CN6C)=C6C=C5)C=C
LY2874455,,1254473-64-7,444.31,FGFR,Protein Tyrosine Kinase/RTK,"LY2874455 is a pan-FGFR inhibitor with IC50s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.",C21H19Cl2N5O2,DMSO : 50 mg/mL (112.53 mM; Need ultrasonic),10mM,Cancer,Phase 2,ClC1=CN=CC(Cl)=C1[C@@H](C)OC2=CC=C(NN=C3/C=C/C4=CN(CCO)N=C4)C3=C2
Irpagratinib,ABSK011,2230974-62-4,570.59,FGFR,Protein Tyrosine Kinase/RTK,"Irpagratinib (ABSK011) is an orally active FGFR4 inhibitor (IC50<10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model[1][2].",C28H32F2N6O5,DMSO : 100 mg/mL (175.26 mM; Need ultrasonic),10mM,Cancer,Phase 2,FC(C(OC)=CC(OC)=C1F)=C1C2=CC(C=N3)=C(C(N4CC(C)(C4)OC)=N2)N=C3N[C@H]5[C@H](CCOC5)NC(C=C)=O
Peficitinib,ASP015K; JNJ-54781532,944118-01-8,326.39,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively[1].",C18H22N4O2,DMSO : 58.33 mg/mL (178.71 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,O[C@](C[C@@H]1C[C@H]2C3)(C2)C[C@@H]3[C@H]1NC4=C5C(NC=C5)=NC=C4C(N)=O
Tivozanib,AV-951; KRN951,475108-18-0,454.86,VEGFR,Protein Tyrosine Kinase/RTK,"Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy[1].",C22H19ClN4O5,DMSO : 25 mg/mL (54.96 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=CC=C(C=C1Cl)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC4=NOC(C)=C4
Gemcitabine elaidate,CP-4126; CO-101; Gemcitabine 5'-elaidate,210829-30-4,527.64,Apoptosis; Autophagy; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,Gemcitabine elaidate (CP-4126) is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated.  Gemcitabine elaidate exhibits anti-tumor activity[1][2].,C27H43F2N3O5,DMSO : ≥ 100 mg/mL (189.52 mM),10mM,Cancer,Launched,O[C@@H](C(F)(F)[C@H](N1C(N=C(C=C1)N)=O)O2)[C@H]2COC(CCCCCCC/C=C/CCCCCCCC)=O
Roginolisib (hemifumarate),MSC2360844 (hemifumarate); IOA-244 (hemifumarate),1621688-31-0,584.62,PI3K,PI3K/Akt/mTOR,"Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases[1].",C26H27FN4O5S.1/2C4H4O4,DMSO : 100 mg/mL (171.05 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(C1=NN(C2=CC=C(CN3CCOCC3)C=C2)C(C4=CC=CC(F)=C45)=C1CS5(=O)=O)N6CCOCC6.OC(/C=C/C(O)=O)=O
Zipalertinib,TAS6417; CLN-081,1661854-97-2,396.44,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM[1][2].",C23H20N6O,DMSO : 22.73 mg/mL (57.34 mM; Need ultrasonic),10mM,Cancer,Phase 3,NC1=C2C(N3C(C(C)=C[C@@H](C3)NC(C=C)=O)=C2C4=CC5=CC=CC=C5N=C4)=NC=N1
Niflumic acid,,4394-00-7,282.22,Chloride Channel; COX,Immunology/Inflammation; Membrane Transporter/Ion Channel,Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis[1][2][3][4][5][6][7][8].,C13H9F3N2O2,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 100 mg/mL (354.33 mM),10mM,Inflammation/Immunology; Cancer,Launched,O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O
SCH 58261,,160098-96-4,345.36,Adenosine Receptor,GPCR/G Protein,"SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC50 of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3 receptors, respectively[1][2][3].",C18H15N7O,DMSO : ≥ 34 mg/mL (98.45 mM),10mM,Cancer,Phase 3,NC1=NC(N(CCC2=CC=CC=C2)N=C3)=C3C4=NC(C5=CC=CO5)=NN14
Terameprocol,EM-1421,24150-24-1,358.47,Apoptosis; COX; Survivin; TNF Receptor,Apoptosis; Immunology/Inflammation,"Terameprocol is an inhibitor targeting the Sp1 transcription factor, which can selectively inhibit the transcription of Sp1-dependent genes. Terameprocol exerts its effects by inhibiting Sp1-mediated gene transcription, such as reducing the expression of genes like CDC2, survivin and HMGB1, thereby arresting the cell cycle, inducing apoptosis, and suppressing the inflammatory response. Terameprocol exhibits anti-proliferative, pro-apoptotic, and anti-inflammatory activities and is currently mainly used in the research of diseases such as cancer and pulmonary arterial hypertension[1][2][3].",C22H30O4,DMSO : 100 mg/mL (278.96 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 2,COC1=CC(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)=CC=C1OC
Bendamustine,SDX-105 (free base),16506-27-7,358.26,Apoptosis; DNA Alkylator/Crosslinker,Apoptosis; Cell Cycle/DNA Damage,"Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].",C16H21Cl2N3O2,DMSO : 100 mg/mL (279.13 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
Ruserontinib,SKLB1028,1350544-93-2,443.55,Bcr-Abl; EGFR; FLT3,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity[1].",C24H29N9,DMSO : 250 mg/mL (563.63 mM; Need ultrasonic),10mM,Cancer,Phase 3,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C4N=C(N(C4=N3)C(C)C)NC5=CC=CN=C5
Taurocholic acid (sodium),Sodium taurocholate; N-Choloyltaurine (sodium),145-42-6,537.68,Endogenous Metabolite; VEGFR,Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect[1].,C26H44NNaO7S,DMSO : ≥ 100 mg/mL (185.98 mM); H2O : 100 mg/mL (185.98 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C
Dofequidar,MS-209 (free base),129716-58-1,481.59,P-glycoprotein,Membrane Transporter/Ion Channel,"Dofequidar (MS-209 free base) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect[1][2].",C30H31N3O3,DMSO : 50 mg/mL (103.82 mM; Need ultrasonic),10mM,Cancer,Phase 1,OC(COC1=C2C=CC=NC2=CC=C1)CN3CCN(C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)CC3
Butylphthalide,3-n-Butylphthalide; 3-Butylphthalide,6066-49-5,190.24,p38 MAPK,MAPK/ERK Pathway,Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.,C12H14O2,DMSO : 250 mg/mL (1314.13 mM; Need ultrasonic),10mM,Neurological Disease,Launched,O=C1OC(CCCC)C2=C1C=CC=C2
Sulindac,MK-231,38194-50-2,356.41,NF-κB; PD-1/PD-L1,Immunology/Inflammation; NF-κB,"Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer[1][2].",C20H17FO3S,DMSO : 50 mg/mL (140.29 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O
Carbimazole,,22232-54-8,186.23,p38 MAPK,MAPK/ERK Pathway,"Carbimazole is an orally active antithyroid agent which rapidly converts to Methimazole after absorption and prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of thyroxine. Carbimazole also displays anti-inflammatory and neuronal-protective activities, suggesting its application for hyperthyroidism and neurological research[1][2][3].",C7H10N2O2S,DMSO : 100 mg/mL (536.97 mM; Need ultrasonic),10mM,Endocrinology; Neurological Disease,Launched,O=C(N1C=CN(C)C1=S)OCC
Cytarabine,Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C,147-94-4,243.22,Apoptosis; Autophagy; DNA/RNA Synthesis; Endogenous Metabolite; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.",C9H13N3O5,DMSO : 17.3 mg/mL (71.13 mM; Need ultrasonic and warming); H2O : 48 mg/mL (197.35 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N
Docetaxel (Trihydrate),RP-56976 (Trihydrate),148408-66-6,861.93,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC50 value of 0.2 μM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].,C43H59NO17,Ethanol : 50 mg/mL (58.01 mM; Need ultrasonic); DMSO : 250 mg/mL (290.05 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(OC(C)(C)C)N[C@H]([C@H](C(O[C@@H]1C(C)=C([C@@H](O)C([C@@]2(C)[C@]([C@@](CO3)(OC(C)=O)[C@@]3([H])C[C@@H]2O)([H])[C@@H]4OC(C5=CC=CC=C5)=O)=O)C(C)(C)[C@@]4(O)C1)=O)O)C6=CC=CC=C6.O.O.O
Histamine,Ergamine,51-45-6,111.15,Akt; Apoptosis; Endogenous Metabolite; Histamine Receptor; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR,"Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma[1][2][3][4][5][6][7].",C5H9N3,H2O : 125 mg/mL (1124.61 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease,Launched,NCCC1=CN=CN1
Golotimod,SCV 07; Gamma-D-glutamyl-L-tryptophan,229305-39-9,333.34,Bacterial; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].",C16H19N3O5,H2O : 125 mg/mL (374.99 mM; Need ultrasonic); DMSO : 50 mg/mL (150.00 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Cancer,Phase 2,O=C(CC[C@@](N)(C(O)=O)[H])N[C@]([H])(C(O)=O)CC1=CNC2=C1C=CC=C2
EOC317,ACTB-1003,939805-30-8,591.53,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"EOC317 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.",C27H26F5N7O3,DMSO : 25 mg/mL (42.26 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC(C(F)(F)F)=CC=C1F)NC2=CC=C(C3=C4C(N)=NC=NN4C(CN5CCOCC5)=C3COC)C=C2F
ARRY-380 (analog),,937265-83-3,569.63,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"ARRY-380 analog, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249[1]. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2[2].",C29H27N7O4S,DMSO : 100 mg/mL (175.55 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OC5=CC6=NC=NN6C=C5)C(C)=C4)N=CN=C3C=C2)O1)(C)=O
Tretazicar,CB 1954,21919-05-1,252.18,DNA Alkylator/Crosslinker; Quinone Reductase,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1)[1][2].",C9H8N4O5,DMSO : 125 mg/mL (495.68 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(N)C1=CC(N2CC2)=C([N+]([O-])=O)C=C1[N+]([O-])=O
Etilefrine,,709-55-7,181.23,Adrenergic Receptor; Akt; AMPK,Epigenetics; GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR,"Etilefrine is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output[1][2][3].",C10H15NO2,DMSO : 40 mg/mL (220.71 mM; Need ultrasonic),10mM,Cardiovascular Disease,Launched,OC(CNCC)C1=CC=CC(O)=C1
Benzoin,DL-Benzoin; Desyl alcohol; (±)-2-Hydroxy-2-phenylacetophenone,119-53-9,212.25,PI3K,PI3K/Akt/mTOR,"Benzoin (DL-Benzoin), a natural balsamic resin, is a PI3Kα inhibitor with anticancer effects. Benzoin inihits the growth of colon cancer cell line (HCT-116). Benzoin can be used as a food additive[1][2].",C14H12O2,DMSO : 50 mg/mL (235.57 mM; Need ultrasonic),10mM,Cancer,Launched,OC(C1=CC=CC=C1)C(C2=CC=CC=C2)=O
Dxd,Exatecan derivative for ADC,1599440-33-1,493.48,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,"Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).",C26H24FN3O6,DMSO : 40 mg/mL (81.06 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5NC(CO)=O)C(C)=C(F)C=C6N=C4C3=C2)=O
Exatecan,DX-8951,171335-80-1,435.45,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,"Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.",C24H22FN3O4,DMSO : 20 mg/mL (45.93 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5N)C(C)=C(F)C=C6N=C4C3=C2)=O
Ferulic acid (sodium),Coniferic acid (sodium),24276-84-4,216.17,Endogenous Metabolite; FGFR; Reactive Oxygen Species (ROS),Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK,"Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.",C10H9NaO4,DMSO : 33.33 mg/mL (154.18 mM; Need ultrasonic); H2O : 100 mg/mL (462.60 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,O=C(O[Na])/C=C/C1=CC=C(O)C(OC)=C1
Gunagratinib,ICP-192,2211082-53-8,423.47,FGFR,Protein Tyrosine Kinase/RTK,"Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1]. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2].",C22H25N5O4,DMSO : 100 mg/mL (236.14 mM; Need ultrasonic),10mM,Cancer,Phase 2,CNC1=C(C(N)=O)C(C#CC2=CC(OC)=CC(OC)=C2)=NN1[C@]3([H])CN(CC3)C(C=C)=O
AMG-208,,1002304-34-8,383.4,c-Met/HGFR; Cytochrome P450,Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,AMG-208 is an orally active c-Met/RON dual selective inhibitor with an IC50 of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity[1][2][3].,C22H17N5O2,DMSO : 3.33 mg/mL (8.69 mM; Need ultrasonic),2mM,Cancer,Phase 2,COC1=CC=C2C(OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5)=CC=NC2=C1
Zoligratinib,Debio 1347; CH5183284,1265229-25-1,356.38,FGFR,Protein Tyrosine Kinase/RTK,"Zoligratinib (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.",C20H16N6O,DMSO : 25 mg/mL (70.15 mM; ultrasonic and warming and heat to 50°C),10mM,Cancer,Phase 2,O=C(C1=C(N)N(C2=CC=C3N=C(C)NC3=C2)N=C1)C(N4)=CC5=C4C=CC=C5
c-Kit-IN-1,,1225278-16-9,489.47,c-Kit; c-Met/HGFR,Protein Tyrosine Kinase/RTK,c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM.,C26H21F2N5O3,DMSO : 100 mg/mL (204.30 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1(CC1)C(NC2=CC=CC=C2)=O)NC3=CC(F)=C(OC4=CC=NC(C5=CN(C)N=C5)=C4)C=C3F
"3,4',5-Trismethoxybenzophenone",,94709-12-3,272.3,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"3,4',5-Trismethoxybenzophenone (compound 16a) is a potent tubulin assembly inhibitor with an IC50 value of 2.6 μM[1].",C16H16O4,10 mM in DMSO,10mM,Cancer,Phase 2,O=C(C1=CC(OC)=CC(OC)=C1)C2=CC=C(OC)C=C2
Fialuridine,FIAU; DRG-0098; NSC 678514,69123-98-4,372.09,DNA/RNA Synthesis; HBV; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus,Anti-infection; Cell Cycle/DNA Damage,"Fialuridine (FIAU), a nucleoside analog, is a HSV-1 and HSV-2 inhibitor with Kis of 0.14 μM and 0.95 μM, respectively. Fialuridine shows anti-orthopoxvirus and anti-hepatitis B virus (HBV) activities. Fialuridine inhibits duck HBV DNA replication with IC50 values of 0.075 μM and 156 μM in human hepatoma cells and in chicken liver cells, respectively[1][2][3].",C9H10FIN2O5,DMSO : 100 mg/mL (268.75 mM; Need ultrasonic),10mM,Infection,Phase 2,O[C@H]1[C@H](F)[C@H](N2C(NC(C(I)=C2)=O)=O)O[C@@H]1CO
Sepantronium (bromide),YM-155,781661-94-7,443.29,Autophagy; Survivin,Apoptosis; Autophagy,Sepantronium bromide (YM-155) is a survivin inhibitor with an IC50 of 0.54 nM[1].,C20H19BrN4O3,DMSO : 11.67 mg/mL (26.33 mM; ultrasonic and warming and heat to 60°C); H2O : 50 mg/mL (112.79 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1C2=C(C(C3=CC=CC=C31)=O)[N+](CC4=NC=CN=C4)=C(C)N2CCOC.[Br-]
Miransertib,ARQ-092,1313881-70-7,432.52,Akt; Parasite,Anti-infection; PI3K/Akt/mTOR,"Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib is effective against Leishmania[2].",C27H24N6,DMSO : 12.5 mg/mL (28.90 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 2,NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5
Gemcitabine,LY 188011,95058-81-4,263.2,Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].",C9H11F2N3O4,DMSO : 200 mg/mL (759.88 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (47.49 mM; Need ultrasonic); H2O : 6.25 mg/mL (23.75 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O
Tunlametinib,HL-085,1801756-06-8,491.25,MEK,MAPK/ERK Pathway,"Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC50=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer)[1][2].",C16H12F2IN3O3S,DMSO : 100 mg/mL (203.56 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CC2=C(C(F)=C1NC3=CC=C(C=C3F)I)N=CS2)NOCCO
MK-2206 (dihydrochloride),MK-2206 (2HCl),1032350-13-2,480.39,Akt; Apoptosis; Autophagy; Organoid,Apoptosis; Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt,"MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active, BBB-penetrated allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy[1][2].",C25H23Cl2N5O,DMSO : 12.5 mg/mL (26.02 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl
Neflamapimod,VX-745,209410-46-8,436.26,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC50 for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.",C19H9Cl2F2N3OS,DMSO : 13.08 mg/mL (29.98 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,O=C1N=CN(C(C=C2)=C1C3=C(Cl)C=CC=C3Cl)N=C2SC4=CC=C(F)C=C4F
Masitinib (mesylate),AB-1010 mesylate,1048007-93-7,594.75,Apoptosis; c-Kit; FGFR; PDGFR; Src,Apoptosis; Protein Tyrosine Kinase/RTK,"Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity[1][2][4].",C29H34N6O4S2,DMSO : ≥ 30 mg/mL (50.44 mM); 1M HCl : 100 mg/mL (168.14 mM; ultrasonic and adjust pH to 1 with HCl),10mM,Cancer,Launched,O=C(NC1=CC=C(C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4.CS(=O)(O)=O
Levofloxacin (hydrate),Levofloxacin hemihydrate,138199-71-0,370.38,Antibiotic; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrate inhibits the DNA gyrase and topoisomerase IV.  Levofloxacin hydrate can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrate shows anti-orthopoxvirus activity[1][2][3][4].",C18H20FN3O4.1/2H2O,DMSO : 50 mg/mL (135.00 mM; ultrasonic and warming and heat to 60°C); H2O : 10 mg/mL (27.00 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O.[0.5H2O]
Lerociclib,G1T38,1628256-23-4,474.6,CDK,Cell Cycle/DNA Damage,"Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.",C26H34N8O,10 mM in DMSO,10mM,Cancer,Phase 3,O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C(C)C)CC6)C=C5)N=C43)CCCCC2
Avitinib (maleate),Abivertinib (maleate); AC0010 (maleate),1557268-88-8,603.6,Apoptosis; Btk; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Avitinib (Abivertinib) maleate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate shows anticancer effects[1][2].",C30H30FN7O6,DMSO : ≥ 100 mg/mL (165.67 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 3,O=C(O)/C=C\C(O)=O.O=C(C=C)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=NC5=C2C=CN5)=C1
Lazertinib,YH25448; GNS-1480,1903008-80-9,554.64,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer[1].",C30H34N8O3,DMSO : 3.33 mg/mL (6.00 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Launched,C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
Tarloxotinib (bromide),TH-4000,1636180-98-7,681.77,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Tarloxotinib bromide (TH-4000) is an irreversible EGFR/HER2 inhibitor.,C24H24Br2ClN9O3,DMSO : ≥ 33 mg/mL (48.40 mM),10mM,Cancer,Phase 2,BrC1=C(Cl)C=CC(NC2=NC=NC3=C2C=C(NC(/C=C/C[N+](C)(C)CC4=C([N+]([O-])=O)N=CN4C)=O)N=C3)=C1.[Br-]
Oclacitinib (monomaleate),PF-03394197 (monomaleate),1640292-55-2,453.51,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Oclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM).,C19H27N5O6S,DMSO : 250 mg/mL (551.26 mM; Need ultrasonic); H2O : 25 mg/mL (55.13 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,O=S(C[C@H]1CC[C@H](N(C)C2=C3C(NC=C3)=NC=N2)CC1)(NC)=O.O=C(O)/C=C\C(O)=O
Garenoxacin (Mesylate hydrate),BMS284756 (Mesylate hydrate),223652-90-2,540.53,Antibiotic; Bacterial; DNA/RNA Synthesis; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Garenoxacin (BMS284756) Mesylate hydrate is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms[1].",C24H26F2N2O8S,DMSO : 100 mg/mL (185.00 mM; Need ultrasonic); H2O : 12.5 mg/mL (23.13 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C1=CN(C2CC2)C3=C(C=CC(C4=CC5=C([C@@H](C)NC5)C=C4)=C3OC(F)F)C1=O)O.CS(=O)(O)=O.O
Ciprofloxacin (hydrochloride monohydrate),Bay-09867 (hydrochloride monohydrate),86393-32-0,385.82,Antibiotic; Apoptosis; Bacterial; Mitochondrial Metabolism; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].",C17H21ClFN3O4,H2O : 20 mg/mL (51.84 mM; Need ultrasonic); DMSO : 5 mg/mL (12.96 mM; ultrasonic and warming and heat to 60°C),10mM,Infection; Cancer,Launched,[H]O[H].[H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
Camptothecin,Campathecin; (S)-(+)-Camptothecin; CPT,7689-03-4,348.36,ADC Payload; Antibiotic; Apoptosis; Fungal; Influenza Virus; MicroRNA; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].",C20H16N2O4,DMSO : 6.25 mg/mL (17.94 mM; Need ultrasonic); 1M NaOH : 10 mg/mL (28.71 mM; ultrasonic and adjust pH to 11 with NaOH),10mM,Cancer; Infection,Launched,O=C1C2=C([C@@](O)(CC)C(OC2)=O)C=C(N1C3)C(C3=C4)=NC5=C4C=CC=C5
Parthenolide,(-)-Parthenolide,20554-84-1,248.32,Apoptosis; Autophagy; Mitophagy; NF-κB,Apoptosis; Autophagy; NF-κB,Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.,C15H20O3,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : ≥ 100 mg/mL (402.71 mM),10mM,Cancer,Phase 2,C/C1=C\CC[C@@](C)(O2)[C@H]2[C@@H](OC(C3=C)=O)[C@H]3CC1
Lirafugratinib,RLY-4008,2549174-42-5,509.53,FGFR,Protein Tyrosine Kinase/RTK,"Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs[1].",C28H24FN7O2,DMSO : 62.5 mg/mL (122.66 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(C(C)=C)NC1=CC=C(C2=C(C3=C(N)N=CN=C3N2C)C4=CC(F)=C(OC5=NC=CC(C)=N5)C=C4)C=C1
Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : 220 mg/mL (544.07 mM; Need ultrasonic); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
GSK3179106,,1627856-64-7,467.41,RET,Protein Tyrosine Kinase/RTK,"GSK3179106 is an orally active and selective RET kinase inhibitor with IC50s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity[1].",C22H21F4N3O4,DMSO : ≥ 100 mg/mL (213.94 mM),10mM,Metabolic Disease; Inflammation/Immunology,Phase 1,O=C(NC1=NOC(C(C)(C)C(F)(F)F)=C1)CC2=CC=C(C(C(OCC)=C3)=CNC3=O)C=C2F
AC-430 (hydrobromide),,1359828-49-1,430.27,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,AC-430 hydrobromide (example 1) is a potent JAK2 inhibitor. AC-430 hydrobromide can be used for the research of myeloproliferative disorders and cancer[1].,C19H17BrFN5O,DMSO : 50 mg/mL (116.21 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC1=CC=C(C(C2=NC(NC3=NNC(C)=C3)=C4C=CC=CC4=N2)O)C=C1.Br
Motesanib,AMG 706,453562-69-1,373.45,c-Kit; VEGFR,Protein Tyrosine Kinase/RTK,"Motesanib (AMG 706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.",C22H23N5O,DMSO : ≥ 100 mg/mL (267.77 mM),10mM,Cancer,Phase 3,O=C(C1=CC=CN=C1NCC2=CC=NC=C2)NC3=CC(NCC4(C)C)=C4C=C3
Dacomitinib (hydrate),PF-00299804 (hydrate); PF-299804 (hydrate),1042385-75-0,487.95,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)[1].",C24H27ClFN5O3,DMF : 10 mg/mL (20.49 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(/C=C/CN1CCCCC1)NC2=CC3=C(C=C2OC)N=CN=C3NC4=CC=C(C(Cl)=C4)F.O
Cytidine,Cytosine β-D-riboside; Cytosine-1-β-D-ribofuranoside,65-46-3,243.22,Endogenous Metabolite; Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function[1][2][3].",C9H13N3O5,H2O : ≥ 50 mg/mL (205.58 mM); DMSO : 50 mg/mL (205.58 mM; Need ultrasonic),10mM,Neurological Disease,Launched,O[C@H]1[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO
Sunitinib (Malate),SU 11248 (Malate),341031-54-7,532.56,Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].",C26H33FN4O7,H2O : 12.5 mg/mL (23.47 mM; ultrasonic and adjust pH to 3 with HCl); DMSO : ≥ 15 mg/mL (28.17 mM); H2O : 12.5 mg/mL (23.47 mM; ultrasonic and adjust pH to 3 with HCl); H2O : 3.33 mg/mL (6.25 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C.O=C([C@H](CC(O)=O)O)O
Ralometostat,TNG908,2760481-53-4,409.5,Histone Methyltransferase,Epigenetics,TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research[1].,C21H23N5O2S,DMSO : 100 mg/mL (244.20 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC1=CC(NC(C(N2[C@@H](C3=CC=C(SC=N4)C4=C3)CC[C@@H](C2)C)=O)=O)=CN=C1N
Capmatinib (dihydrochloride hydrate),INC280 (dihydrochloride hydrate); INCB-28060 (dihydrochloride hydrate),1865733-40-9,503.36,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].",C23H21Cl2FN6O2,DMSO : 20.83 mg/mL (41.38 mM; ultrasonic and warming and heat to 60°C); H2O : 3.33 mg/mL (6.62 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F.O.Cl.Cl
Perillyl alcohol,,536-59-4,152.24,Akt; Apoptosis; Caspase; Ras; Reactive Oxygen Species (ROS),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Perillyl alcohol is an orally active monoterpene. Perillyl alcohol exhibits multiple activities such as analgesic, anti-inflammatory, anti-tumor, anti-angiogenic, and anti-nociceptive effects. Perillyl alcohol can induce apoptosis and cell cycle arrest in tumor cells[1][2][3][4].",C10H16O,DMSO : 100 mg/mL (656.86 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Phase 1,OCC1=CCC(C(C)=C)CC1
Altiratinib,DCC-2701,1345847-93-9,510.46,c-Met/HGFR; FLT3; Trk Receptor; VEGFR,Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.",C26H21F3N4O4,DMSO : 25 mg/mL (48.98 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC(F)=C(OC4=CC(NC(C5CC5)=O)=NC=C4)C=C3F
Pamapimod,Ro4402257; R1503,449811-01-2,406.38,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1].",C19H20F2N4O4,DMSO : ≥ 34 mg/mL (83.67 mM),10mM,Inflammation/Immunology,Launched,O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C
Bafetinib,INNO-406; NS-187,859212-16-1,576.62,Apoptosis; Bcr-Abl; Src,Apoptosis; Protein Tyrosine Kinase/RTK,"Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph+ leukemia cells. Bafetinib has antitumor activity[1][2][3].",C30H31F3N8O,DMSO : 100 mg/mL (173.42 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CC=C(C(C(F)(F)F)=C1)CN2C[C@@H](N(C)C)CC2)NC3=CC=C(C)C(NC4=NC=CC(C5=CN=CN=C5)=N4)=C3
MAX-10181,PD-1/PD-L1-IN-30,2171558-14-6,527.53,PD-1/PD-L1,Immunology/Inflammation,"MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor, with an IC50 value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases[1].",C29H28F3NO5,DMSO : 100 mg/mL (189.56 mM; Need ultrasonic),10mM,Cancer,Phase 1,CC1=C(C=CC=C1/C=C/C2=C(C=CC(CNC(CO)(C)C(O)=O)=C2)C(F)(F)F)C3=CC=C(OCCO4)C4=C3
Futibatinib,TAS-120,1448169-71-8,418.45,FGFR,Protein Tyrosine Kinase/RTK,"Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9?nM; V5651=1-3?nM; N550H=3.6?nM; E566G=2.4?nM)[1][2][3].",C22H22N6O3,DMSO : ≥ 29 mg/mL (69.30 mM),10mM,Cancer,Launched,O=C(C=C)N(C1)CC[C@@H]1N(N=C2C#CC3=CC(OC)=CC(OC)=C3)C4=C2C(N)=NC=N4
AZD-1480,,935666-88-9,348.77,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AZD-1480 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50s?of 1.3 nM and <0.4?nM, respectively[1].",C14H14ClFN8,DMSO : 50 mg/mL (143.36 mM; Need ultrasonic),10mM,Cancer,Phase 2,ClC1=C(N=C(N=C1)N[C@@H](C)C2=NC=C(C=N2)F)NC3=NNC(C)=C3
Debio 0932,CUDC-305,1061318-81-7,442.58,HSP,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Debio 0932 (CUDC-305) is an orally active HSP90 inhibitor, with IC50s of 100 and 103 nM for HSP90α and HSP90β, respectively[1].",C22H30N6O2S,DMSO : 75 mg/mL (169.46 mM; Need ultrasonic),10mM,Cancer,Phase 1,NC1=NC=CC2=C1N=C(SC3=C(N(C)C)C=C(OCO4)C4=C3)N2CCNCC(C)(C)C
Varenicline (Tartrate),CP 526555-18,375815-87-5,361.35,ERK; nAChR; p38 MAPK,MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; Stem Cell/Wnt,"Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].",C17H19N3O6,DMSO : 14.29 mg/mL (39.55 mM; Need ultrasonic); H2O : 20 mg/mL (55.35 mM; ultrasonic and warming and heat to 60°C),10mM,Neurological Disease; Others; Cancer,Launched,O=C(O)[C@H](O)[C@@H](O)C(O)=O.C1(C2CC3CNC2)=C3C=C(N=CC=N4)C4=C1
Zotiraciclib,TG02; SB1317,1204918-72-8,372.46,CDK; FLT3; JAK,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma[1][2].",C23H24N4O,DMSO : 100 mg/mL (268.49 mM; Need ultrasonic),10mM,Cancer,Phase 2,CN1CC2=CC(NC3=NC(C4=CC(OCC/C=C/C1)=CC=C4)=CC=N3)=CC=C2
Gusacitinib,ASN-002,1425381-60-7,460.53,JAK; Syk,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma[1][2].",C24H28N8O2,DMSO : 100 mg/mL (217.14 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,N#CCC1CCN(C2=NC(NC3=CC=C(N4CCC(O)CC4)C=C3)=C5C(C=NNC5=O)=N2)CC1
Peldesine (dihydrochloride),BCX 34 (dihydrochloride),2772702-10-8,314.17,HIV; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,"Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research[1][2][3][4].",C12H13Cl2N5O,H2O : 33.33 mg/mL (106.09 mM; Need ultrasonic); DMSO : 200 mg/mL (636.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 1,Cl[H].O=C1C(NC=C2CC3=CC=CN=C3)=C2N=C(N)N1.Cl[H]
Teneligliptin (hydrobromide hydrate),MP-513 (hydrobromide hydrate),1572583-29-9,426.58,AMPK; Apoptosis; Interleukin Related; JNK; NF-κB; NOD-like Receptor (NLR); p38 MAPK; Reactive Oxygen Species (ROS); Toll-like Receptor (TLR),Apoptosis; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus[1][2][3][4][5][6][7][8].",C22H30N6OS,H2O : ≥ 100 mg/mL (234.42 mM),10mM,Metabolic Disease; Neurological Disease; Cardiovascular Disease,Launched,O=C([C@H]1NC[C@@H](N2CCN(C3=CC(C)=NN3C4=CC=CC=C4)CC2)C1)N5CSCC5.[x H2O].[5/2 HBr]
ABN401,,2242563-15-9,566.66,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"ABN401 is an orally active and selective ATP-competitive c-MET inhibitor with an IC50 of 10 nM. ABN401 is cytotoxic to MET-addicted cancer cells with the IC50 of 2-43 nM. ABN401 has bioavailability in rats and dogs of 42.1-56.2% and 27.4-37.7%, respectively. ABN401 has antitumor activity[1][2].",C29H34N12O,DMSO : 10 mg/mL (17.65 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CN1N=CC(C2=CN=C3C(N(CC4CN(C5=NC=C(C6=CC=C(CN7CCN(C)CC7)C=C6)C=N5)CCO4)N=N3)=N2)=C1
Davunetide,,211439-12-2,824.92,Amyloid-β; Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton; Neuronal Signaling,"Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic.  Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity[1][2][3].",C36H60N10O12,H2O : 100 mg/mL (121.22 mM; Need ultrasonic); DMSO : 125 mg/mL (151.53 mM; Need ultrasonic),10mM,Neurological Disease,Phase 3,O=C(N(CCC1)[C@@H]1C(N[C@H](C(O)=O)CCC(N)=O)=O)[C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CCC2)N2C([C@H](C)NC([C@@H](N)CC(N)=O)=O)=O)=O)=O)=O
E7090,,1622204-21-0,587.67,FGFR,Protein Tyrosine Kinase/RTK,"E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively[1].",C32H37N5O6,DMSO : 100 mg/mL (170.16 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(N1C=CC2=C1C=C(OCCOC)C(OC3=CC(NC(C4=CC=C(C5CCN(CCO)CC5)C=C4)=O)=NC=C3)=C2)NC
Axitinib,AG-013736,319460-85-0,386.47,PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and  PDGFRβ, respectively.",C22H18N4OS,DMSO : 20.83 mg/mL (53.90 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(SC2=CC3=C(C(/C=C/C4=CC=CC=N4)=NN3)C=C2)C=CC=C1)NC
Berberine (chloride hydrate),Natural Yellow 18 (chloride hydrate),68030-18-2,389.83,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride hydrate (Natural Yellow 18 chloride hydrate) is an alkaloid that acts as an antibiotic. Berberine chloride hydrate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H20ClNO5,DMSO : ≥ 3.9 mg/mL (10.00 mM); H2O : 1 mg/mL (2.57 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-].O
AZ7550,,1421373-99-0,485.58,Drug Metabolite; EGFR; IGF-1R,JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.,C27H31N7O2,DMSO : 83.33 mg/mL (171.61 mM; ultrasonic and adjust pH to 5 with 1 M HCL),10mM,Cancer; Endocrinology,Phase 1,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(C)CCNC)=O
Plinabulin,NPI-2358,714272-27-2,336.39,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells[1]. Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells[2].,C19H20N4O2,DMSO : 50 mg/mL (148.64 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(N/C1=C\C2=C(NC=N2)C(C)(C)C)/C(NC1=O)=C/C3=CC=CC=C3
Linperlisib,YY-20394,1702816-75-8,588.69,PI3K,PI3K/Akt/mTOR,"Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC50 of 6.4 nM[1].",C28H37FN6O5S,DMSO : 100 mg/mL (169.87 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,CS(=O)(NC1=CC(C2=C3C=C(F)C=C(CN4CCC(C(C)(O)C)CC4)C3=NC(N5CCOCC5)=N2)=CN=C1OC)=O
Bozitinib,PLB-1001; CBT-101; Vebreltinib,1440964-89-5,424.38,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].",C20H15F3N8,DMSO : 50 mg/mL (117.82 mM; Need ultrasonic),10mM,Cancer,Phase 3,CN1N=C2C=C(F)C(C(C3=NN=C4C=CC(C5=CN(C6CC6)N=C5)=NN43)(F)F)=CC2=C1
Imofinostat,ABT-301; MPT0E028; TMU-C-0012,1338320-94-7,344.38,Akt; Apoptosis; HDAC,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 ??μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis[1][2][3][14][5][6].",C17H16N2O4S,DMSO : 100 mg/mL (290.38 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 1,O=C(/C=C/C1=CC2=C(C=C1)N(CC2)S(=O)(C3=CC=CC=C3)=O)NO
Orantinib,SU6668; TSU-68,252916-29-3,310.35,Apoptosis; FGFR; PDGFR; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.",C18H18N2O3,DMSO : 100 mg/mL (322.22 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC1=C(/C=C2C3=CC=CC=C3NC/2=O)NC(C)=C1CCC(O)=O
Ergothioneine,L-(+)-Ergothioneine,497-30-3,229.31,Akt; Endogenous Metabolite; Keap1-Nrf2; NF-κB; p38 MAPK,MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Ergothioneine is an imidazole-2-thione derivative with orally active histidine betaine. Ergothioneine is a specific inhibitor of p38-MAPK and Akt, which plays a protective role in cell apoptosis induced by stress. Ergothioneine has antioxidant activity[1][2].",C9H15N3O2S,H2O : 125 mg/mL (545.13 mM; Need ultrasonic),10mM,Others,Phase 3,S=C1NC(C[C@@H](C([O-])=O)[N+](C)(C)C)=CN1
Acenocoumarol,,152-72-7,353.33,Akt; Apoptosis; ERK; GSK-3; JNK; NF-κB; p38 MAPK; PKA; VD/VDR,Apoptosis; MAPK/ERK Pathway; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad; Vitamin D Related/Nuclear Receptor,"Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase[1][2][3][4].",C19H15NO6,DMSO : 100 mg/mL (283.02 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Cardiovascular Disease,Launched,O=C1C(C(C2=CC=C([N+]([O-])=O)C=C2)CC(C)=O)=C(O)C3=CC=CC=C3O1
AG-270,,2201056-66-6,489.57,Methionine Adenosyltransferase (MAT),Epigenetics; Metabolic Enzyme/Protease,"AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM[1].",C30H27N5O2,DMSO : 4 mg/mL (8.17 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 1,O=C1C(C2=CC=C(OC)C=C2)=C(NC3=NC=CC=C3)NC4=C(C5=CCCCC5)C(C6=CC=CC=C6)=NN14
MAX-40279 (hemiadipate),,2388506-44-1,584.66,FGFR; FLT3,Protein Tyrosine Kinase/RTK,MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1].,C22H23FN6OS.1/2C6H10O4,DMSO : 25 mg/mL (42.76 mM; ultrasonic and warming and heat to 60°C); DMF : 10 mg/mL (17.10 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(O)CCCCC(O)=O.FC1=CC(OC)=C(C2=C(C)SC3=C2N=C(NC4=CN(C5CCNCC5)N=C4)N=C3)C=C1
PKI-179 (hydrochloride),,1463510-35-1,525.0,mTOR; PI3K,PI3K/Akt/mTOR,"PKI-179 hydrochloride is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 hydrochloride also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride shows anti-tumor activity in vivo[1][2].",C25H29ClN8O3,DMSO : 20 mg/mL (38.10 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC=NC=C1)NC2=CC=C(C3=NC(N4C5CCC4COC5)=NC(N6CCOCC6)=N3)C=C2.Cl
Suramin (sodium salt),Suramin (hexasodium salt),129-46-4,1429.17,Apoptosis; Parasite; Phosphatase; Reverse Transcriptase; SARS-CoV; Sirtuin; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease,"Suramin sodium salt	(Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor[1]. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM)[2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM)[3][4]. Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor[5]. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent[6][7][8].",C51H34N6Na6O23S6,DMSO : 83.33 mg/mL (58.31 mM; Need ultrasonic); H2O : 50 mg/mL (34.99 mM; Need ultrasonic),10mM,Cancer; Infection; Cardiovascular Disease,Launched,O=C(NC1=CC(C(NC2=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C4=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C34)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)(O[Na])=O)C8=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C78)=O)=CC=C6C)=O)=CC=C5
Olafertinib,CK-101; RX518,1660963-42-7,530.57,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Olafertinib (CK-101) is an orally available, third generation and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Olafertinib selectively inhibits both EGFR-TKI-sensitizing and resistance mutations with minimal activity on wild-type EGFR. Olafertinib can be used in research for non-small cell lung cancer (NSCLC) with EGFR mutations and other advanced malignancies[1][2].",C29H28F2N6O2,DMSO : 125 mg/mL (235.60 mM; Need ultrasonic),10mM,Cancer,Phase 2,OCCN1CCN(C2=C(F)C(F)=C(NC3=NC=C4C(C(C5=CC(NC(C=C)=O)=CC=C5)=CC=C4)=N3)C=C2)CC1
Tomivosertib,eFT508,1849590-01-7,340.38,MNK; PD-1/PD-L1,Immunology/Inflammation; MAPK/ERK Pathway,"Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines[1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance[2].",C17H20N6O2,DMSO : 4.35 mg/mL (12.78 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C(C)C=C(NC2=NC=NC(N)=C2)C(N13)=O)NC43CCCCC4
Vatalanib (dihydrochloride),PTK787 (dihydrochloride); ZK-222584 (dihydrochloride); CGP-797870 (dihydrochloride),212141-51-0,419.73,Apoptosis; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.,C20H17Cl3N4,DMSO : 50 mg/mL (119.12 mM; ultrasonic and warming and heat to 80°C); H2O : 50 mg/mL (119.12 mM; Need ultrasonic),10mM,Cancer,Phase 3,ClC1=CC=C(C=C1)NC2=NN=C(C3=C2C=CC=C3)CC4=CC=NC=C4.[H]Cl.[H]Cl
Genz-644282,,529488-28-6,407.42,Topoisomerase,Cell Cycle/DNA Damage,"Genz-644282 is a non-camptothecin topoisomerase I inhibitor, used for cancer research.",C22H21N3O5,DMSO : 3.64 mg/mL (8.93 mM; ultrasonic and warming and heat to 75°C),2mM,Cancer,Phase 1,O=C1N(CCNC)C2=C(C=NC(C2=C3)=CC4=C3OCO4)C5=CC(OC)=C(OC)C=C15
BMS-911543,,1271022-90-2,432.52,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"BMS-911543 is a selective JAK2 inhibitor, with IC50s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC50, 75, 360, 66 nM, respectively).",C23H28N8O,DMSO : 25 mg/mL (57.80 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CC2=C(N(C)C=N3)C3=C(NC4=NN(C)C(C)=C4)N=C2N1CC)N(C5CC5)C6CC6
Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
KO-947,,1695533-89-1,355.39,ERK,MAPK/ERK Pathway; Stem Cell/Wnt,KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential utility in MAPK pathway dysregulated tumors.,C21H17N5O,DMSO : 62.5 mg/mL (175.86 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1NC2=CC(NN=C3C4=CC=NC=C4)=C3C=C2CN1CC5=CC=CC=C5
Chiauranib,Ibcasertib; CS2164,1256349-48-0,435.47,Aurora Kinase; c-Fms; c-Kit; PDGFR; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects[1].",C27H21N3O3,DMSO : 62.5 mg/mL (143.52 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=CC=CC=C1N)C2=C3C=CC(OC4=CC=NC5=CC(OC)=CC=C54)=CC3=CC=C2
Ruxolitinib,INCB18424,941678-49-5,306.37,Apoptosis; Autophagy; JAK; Mitophagy,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].",C17H18N6,DMSO : ≥ 100 mg/mL (326.40 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2
Sabizabulin,VERU-111; ABI-231,1332881-26-1,377.39,Apoptosis; HPV; Microtubule/Tubulin,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC50 of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer[1][2][3].",C21H19N3O4,DMSO : 20 mg/mL (53.00 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CNC(C2=CNC3=C2C=CC=C3)=N1)C4=CC(OC)=C(OC)C(OC)=C4
Saracatinib,AZD0530,379231-04-6,542.03,Autophagy; Src,Autophagy; Protein Tyrosine Kinase/RTK,"Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases[1].",C27H32ClN5O5,DMSO : 50 mg/mL (92.25 mM; Need ultrasonic),10mM,Cancer,Phase 3,ClC1=CC=C2C(OCO2)=C1NC3=C4C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=CC4=NC=N3
Fumaric acid,,110-17-8,116.07,Endogenous Metabolite; NF-κB; p38 MAPK,MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB,"Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension[1][2][3].",C4H4O4,H2O : 11.11 mg/mL (95.72 mM; Need ultrasonic); DMSO : 25 mg/mL (215.39 mM; Need ultrasonic),10mM,Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,O=C(O)/C=C/C(O)=O
Simufilam,PTI-125,1224591-33-6,259.35,Amyloid-β; iGluR; mTOR; Tau Protein,Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR,"Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. 
Simufilam can be used for research of Alzheimer's disease[1][2][3].",C15H21N3O,DMSO : 50 mg/mL (192.79 mM; Need ultrasonic),10mM,Neurological Disease,Phase 3,O=C1N(CC2=CC=CC=C2)C3(CCN(C)CC3)NC1
Sorafenib,Bay 43-9006,284461-73-0,464.83,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].",C21H16ClF3N4O3,DMSO : ≥ 45 mg/mL (96.81 mM),10mM,Cancer,Launched,O=C(NC(C=C1)=CC=C1OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Lerociclib (dihydrochloride),G1T38 (dihydrochloride),2097938-59-3,547.52,CDK,Cell Cycle/DNA Damage,"Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.",C26H36Cl2N8O,H2O : 5 mg/mL (9.13 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 3,O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C(C)C)CC6)C=C5)N=C43)CCCCC2.Cl.Cl
Roblitinib,FGF-401,1708971-55-4,506.56,FGFR,Protein Tyrosine Kinase/RTK,Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM[1]. Roblitinib has antitumor activity[2].,C25H30N8O4,DMSO : 5 mg/mL (9.87 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 2,CN1CC(N(CC2=CC(CCCN3C(NC4=CC(NCCOC)=C(C#N)C=N4)=O)=C3N=C2C=O)CC1)=O
Ensartinib,X-396,1370651-20-9,561.44,Anaplastic lymphoma kinase (ALK); c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74  nM, respectively.",C26H27Cl2FN6O3,DMSO : 100 mg/mL (178.11 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4C[C@@H](C)N[C@@H](C)C4)=O)C=C3
Losmapimod,GSK-AHAB; GW856553X; SB856553,585543-15-3,383.46,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively[1].",C22H26FN3O2,DMSO : 27.5 mg/mL (71.72 mM; Need ultrasonic); Ethanol : 33.33 mg/mL (86.92 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 3,CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F
Galunisertib,LY2157299,700874-72-2,369.42,TGF-β Receptor,TGF-beta/Smad,Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.,C22H19N5O,DMSO : 100 mg/mL (270.69 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC1=CC=CC(C2=NN3C(CCC3)=C2C4=CC=NC5=C4C=C(C=C5)C(N)=O)=N1
Pamiparib,BGB-290,1446261-44-4,298.32,PARP,Cell Cycle/DNA Damage; Epigenetics,"Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor, with IC50 values of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively. Pamiparib has potent PARP trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor[1][2].",C16H15FN4O,DMSO : 50 mg/mL (167.60 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1NN=C2CN(CCC3)[C@@]3(C)C(N4)=C2C5=C4C=C(F)C=C51
Varlitinib,ASLAN001; ARRY-334543,845272-21-1,466.94,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively[1].",C22H19ClN6O2S,DMSO : 33.33 mg/mL (71.38 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,C[C@H]1N=C(NC2=CC3=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)N=CN=C3C=C2)OC1
Samotolisib,LY3023414,1386874-06-1,406.48,Autophagy; DNA-PK; mTOR; PI3K,Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations[1][2].",C23H26N4O3,DMSO : 50 mg/mL (123.01 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(N1C[C@@H](OC)C)N(C)C2=C1C3=CC(C4=CC(C(C)(O)C)=CN=C4)=CC=C3N=C2
Forodesine (hydrochloride),BCX-1777 (hydrochloride); Immucillin-H (hydrochloride),284490-13-7,302.71,Apoptosis; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage,"Forodesine hydrochloride (BCX-1777 hydrochloride) is a highly potent and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50 values ranging from 0.48 to 1.57 nM for human, mouse, rat, monkey and dog PNP. Forodesine hydrochloride is a potent human lymphocyte proliferation inhibitor. Forodesine hydrochloride could induce apoptosis in leukemic cells by increasing the dGTP levels[1][2].",C11H15ClN4O4,H2O : 100 mg/mL (330.34 mM; Need ultrasonic); DMSO : 10 mg/mL (33.03 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C(NC=C2[C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)=C2NC=N1.Cl
Icaritin,Anhydroicaritin,118525-40-9,368.38,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC50  of 8 μM) and primary CML cells (IC50  of 13.4 μM for CML-CP and 18 μM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis[1][2][3.",C21H20O6,DMSO : 15.62 mg/mL (42.40 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C13
VS-5584,SB2343,1246560-33-7,354.41,mTOR; PI3K,PI3K/Akt/mTOR,"VS-5584 is a pan-PI3K/mTOR kinase inhibitor with IC50s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.",C17H22N8O,DMSO : 33.33 mg/mL (94.04 mM; Need ultrasonic),10mM,Cancer,Phase 1,NC1=NC=C(C2=C3N=C(C)N(C(C)C)C3=NC(N4CCOCC4)=N2)C=N1
Momelotinib,CYT387,1056634-68-4,414.46,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.",C23H22N6O2,DMSO : 10 mg/mL (24.13 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)C=C1)NCC#N
SU14813,,627908-92-3,442.48,c-Kit; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.",C23H27FN4O4,DMSO : 44 mg/mL (99.44 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(/C(C1=C2)=C/C3=C(C(C(NC[C@H](O)CN4CCOCC4)=O)=C(N3)C)C)NC1=CC=C2F
Ifidancitinib,ATI-50002; ATI-502,1236667-40-5,395.39,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ifidancitinib (ATI-50002) is an orally available, potent and selective inhibitor of JAK kinase 1/3 that disrupts γc cytokine signaling. Ifidancitinib is used in the research of allergy, asthma, and autoimmune diseases[1][2].",C20H18FN5O3,DMSO : 62.5 mg/mL (158.07 mM; Need ultrasonic),10mM,Inflammation/Immunology; Others,Phase 2,O=C1OC2=CC=C(NC3=NC(NC4=CC(C)=C(F)C(OC)=C4)=NC=C3C)C=C2N1
Bendamustine (hydrochloride),SDX-105,3543-75-7,394.72,Apoptosis; DNA Alkylator/Crosslinker,Apoptosis; Cell Cycle/DNA Damage,"Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1].",C16H22Cl3N3O2,DMSO : 100 mg/mL (253.34 mM; Need ultrasonic); H2O : 10 mg/mL (25.33 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C=CC(N(CCCl)CCCl)=C2)=C2N=C1CCCC(O)=O.Cl
SAR125844,,1116743-46-4,550.63,Akt; Apoptosis; c-Met/HGFR; MEK; PI3K,Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"SAR125844 is a potent, selective, and ATP-competitive MET kinase inhibitor with the value of IC50 is 4.2 nM and Ki is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer[1][2][3].",C25H23FN8O2S2,DMSO : 45 mg/mL (81.72 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NCCN1CCOCC1)NC2=NC3=CC=C(SC4=NN=C5C=CC(C6=CC=C(F)C=C6)=NN54)C=C3S2
